Dysregulation of the Immune System in a Natural History Study of 1299 Individuals with Down Syndrome.
Autoimmune
Down Syndrome
Dysregulation
Inflammation
Natural History
Viral Disease
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
received:
20
11
2023
accepted:
26
04
2024
medline:
22
5
2024
pubmed:
22
5
2024
entrez:
22
5
2024
Statut:
epublish
Résumé
Dysregulation of the immune system in individuals with Down syndrome is thought to play a major role in the pathophysiology of many clinical presentations. This natural history of disease study took a comprehensive evaluation of the prevalence of different immune related diagnoses in a cohort of 1299 patients with Down syndrome compared to a 2605 patient control cohort at the Mount Sinai Health System in New York, NY over the past 18 years. We conducted a stepwise analysis of the odds of receiving a diagnosis at the Chapter, Sub-chapter and Diagnosis level of the ICD-CM-10 code system. Individuals in our Down syndrome cohort had higher odds of a diagnosis with inflammatory and autoimmune presentations such as Alopecia areata (OR 6.06, p = 0.01), Other sepsis (OR 4.79, p < 0.001, Purpura and other hemorrhagic conditions (OR 2.31, p < 0.001), and Rosacea (OR 3.11, p < 0.001). They also presented with lower odds of a diagnosis of Herpesviral infection (OR 0.42, p = 0.01), and Viral warts (OR 0.51, p = 0.04). We posit that dysregulation of the immune system in individuals with Down syndrome has impact on infectious diseases, including lowering the incidence of viral disease and increasing its severity. Our data also suggests inflammation and autoimmune mediated diseases, in particular of the skin, are exacerbated in individuals with Down syndrome. Finally, there may be a need for greater clinical attention to non-emergent conditions within the Down syndrome patient population as those can also greatly affect quality of life.
Identifiants
pubmed: 38776031
doi: 10.1007/s10875-024-01725-6
pii: 10.1007/s10875-024-01725-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Subventions
Organisme : National Institute of Allergy and Infectious Diseases
ID : 3R01AI150300-01S2
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lagan N, Huggard D, McGrane F, Leahy TR, Franklin O, Roche E, Webb D, O’ Marcaigh A, Cox D, El-Khuffash A, Greally P, Balfe J, Molloy EJ. Multiorgan involvement and management in children with Down syndrome. Acta Paediatr. 2020;109(6):1096–111. https://doi.org/10.1111/apa.15153 .
doi: 10.1111/apa.15153
pubmed: 31899550
Bull MJ, Down Syndrome. N Engl J Med. 2020;382(24):2344–52. https://doi.org/10.1056/NEJMra1706537 .
doi: 10.1056/NEJMra1706537
pubmed: 32521135
Malle L, Bogunovic D. Down syndrome and type I interferon: not so simple. Curr Opin Immunol. 2021;72:196–205. https://doi.org/10.1016/j.coi.2021.06.006 .
doi: 10.1016/j.coi.2021.06.006
pubmed: 34174697
pmcid: 8578175
Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH. Down syndrome. Nat Rev Dis Primers. 2020;6(1):9. https://doi.org/10.1038/s41572-019-0143-7 .
doi: 10.1038/s41572-019-0143-7
pubmed: 32029743
pmcid: 8428796
Arumugam A, Raja K, Venugopalan M, Chandrasekaran B, Kovanur Sampath K, Muthusamy H, Shanmugam N. Down syndrome-A narrative review with a focus on anatomical features. Clin Anat. 2016;29(5):568–77. https://doi.org/10.1002/ca.22672 .
doi: 10.1002/ca.22672
pubmed: 26599319
Roizen NJ, Patterson D. Down’s syndrome. Lancet. 2003;361(9365):1281–9. https://doi.org/10.1016/S0140-6736(03)12987-X .
doi: 10.1016/S0140-6736(03)12987-X
pubmed: 12699967
Araya P, Waugh KA, Sullivan KD, Núñez NG, Roselli E, Smith KP, Granrath RE, Rachubinski AL, Enriquez Estrada B, Butcher ET, Minter R, Tuttle KD, Bruno TC, Maccioni M, Espinosa JM. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc Natl Acad Sci U S A. 2019;116(48):24231–41. https://doi.org/10.1073/pnas.1908129116 .
doi: 10.1073/pnas.1908129116
pubmed: 31699819
pmcid: 6883781
Malle L, Martin-Fernandez M, Buta S, Richardson A, Bush D, Bogunovic D. Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome. Immunity. 2022;55(11):2074–e20845. https://doi.org/10.1016/j.immuni.2022.09.007 .
doi: 10.1016/j.immuni.2022.09.007
pubmed: 36243008
pmcid: 9649881
Kong XF, Worley L, Rinchai D, Bondet V, Jithesh PV, Goulet M, Nonnotte E, Rebillat AS, Conte M, Mircher C, Gürtler N, Liu L, Migaud M, Elanbari M, Habib T, Ma CS, Bustamante J, Abel L, Ravel A, Lyonnet S, Munnich A, Duffy D, Chaussabel D, Casanova JL, Tangye SG, Boisson-Dupuis S, Puel A. Three copies of four Interferon receptor genes underlie a mild type I interferonopathy in Down Syndrome. J Clin Immunol. 2020;40(6):807–19. https://doi.org/10.1007/s10875-020-00803-9 .
doi: 10.1007/s10875-020-00803-9
pubmed: 32572726
pmcid: 7418179
Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM. Trisomy 21 consistently activates the interferon response. Elife. 2016;5:e16220. https://doi.org/10.7554/eLife.16220 .
doi: 10.7554/eLife.16220
pubmed: 27472900
pmcid: 5012864
Malle L, Patel RS, Martin-Fernandez M, Stewart OJ, Philippot Q, Buta S, Richardson A, Barcessat V, Taft J, Bastard P, Samuels J, Mircher C, Rebillat AS, Maillebouis L, Vilaire-Meunier M, Tuballes K, Rosenberg BR, Trachtman R, Casanova JL, Notarangelo LD, Gnjatic S, Bush D, Bogunovic D. Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c
doi: 10.1038/s41586-023-05736-y
pubmed: 36813963
pmcid: 9945839
About ATLAS. | Mount Sinai Data Warehouse. Labs.icahn.mssm.edu 2021 [cited 2023 Nov 16]. https://labs.icahn.mssm.edu/msdw/about-atlas/ .
ICD-10-CM. Cdc.goc. 2020. Avaialble from: https://icd10cmtool.cdc.gov/I .
Chicoine B, Rivelli A, Fitzpatrick V, Chicoine L, Jia G, Rzhetsky A. Prevalence of Common Disease conditions in a large cohort of individuals with Down Syndrome in the United States. J Patient Cent Res Rev. 2021;8(2):86–97. https://doi.org/10.17294/2330-0698.1824 .
doi: 10.17294/2330-0698.1824
pubmed: 33898640
pmcid: 8060042
Malle L, Gao C, Hur C, Truong HQ, Bouvier NM, Percha B, Kong XF, Bogunovic D. Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. Genet Med. 2021;23(3):576–80. https://doi.org/10.1038/s41436-020-01004-w .
doi: 10.1038/s41436-020-01004-w
pubmed: 33060835
pmcid: 7936948
Verstegen RHJ, Chang KJJ, Kusters MAA. Clinical implications of immune-mediated diseases in children with Down syndrome. Pediatr Allergy Immunol. 2020;31(2):117–23. https://doi.org/10.1111/pai.13133 .
doi: 10.1111/pai.13133
pubmed: 31599041
Zhang Y, Che M, Yuan J, Yu Y, Cao C, Qin XY, Cheng Y. Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis. Oncotarget. 2017;8(48):84489–96. https://doi.org/10.18632/oncotarget.21060 .
doi: 10.18632/oncotarget.21060
pubmed: 29137441
pmcid: 5663613